Skip to main content

Table 1 Clinical characteristics of patients enrolled in this study according to TP53 status

From: Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing

Clinical characteristics No. of patients TP53 p value
Wild type Mutated
Total 153 63 (41.18%) 90 (58.82%)  
Gender
 Male 103 36 67 0.025*
 Female 50 27 23  
Age median (range) 59 (19–80)    
Stage
 I 25 12 13 0.206
 II 39 18 21  
 III 69 22 47  
Lauren classification
 Diffuse 50 23 27 0.163
 Intestinal 47 13 34  
 Mixed 24 10 14  
Differentiation
 Poorly 62 29 33 0.21
 Moderately and poorly 27 9 18  
 Moderately 45 14 31  
Location
 Cardia 24 4 20 0.011*
 Gastric (fundus, body, antrum, pylorus) 122 56 66  
Lymphatic metastasis
 Yes 89 31 58 0.067
 No 47 24 23  
Drinking
 Yes 21 6 15 0.228
 No 127 54 73  
Smoke
 Yes 30 10 20 0.368
 No 118 50 68  
HER-2 IHC
 Positive 11 2 9 0.208
 Negative 110 43 67  
  1. Patients were not showed whose clinical data was missing
  2. * p < 0.05, ** p < 0.01, *** p < 0.001